The Annual Economic Burden of RSV in Adults in the US, Recombinant or Standard-Dose Influenza Vaccine in Adults Under 65 Years of Age, and Optimal Timing of Nirmatrelvir/Ritonavir Treatment After COVID-19 Symptom Onset or Diagnosis
Comments 0
Login to view comments.
Click here to Login
